Phase 1 Migraine Trial, Recruiting NCT06995729 Sponsor: Pfizer Condition: Migraine
Back to Migraine

Phase 1 Migraine Trial, Recruiting

NCT06995729
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children between 6 and 11 years old (up to but not including 12 years).
  • Children who have a documented medical history of migraines (with or without visual or sensory disturbances before the headache) for at least 6 months before the initial screening appointment.
  • Children who weigh more than 15 kg at the initial screening appointment.

Who may not be able to join:

  • Children who have evidence or a history of another significant medical condition.
  • Children who have had a continuous, non-stop headache in the month before the screening appointment.
  • Children whose migraines are of an unusual type, involve complications, or who have another significant pain condition that could interfere with the trial.
  • Children who have any condition that could affect how a nasal spray medicine is given or absorbed into the body (confirm with trial site).
  • Children who have an uncontrolled or untreated mental health condition, including significant depression or any thoughts or behaviours related to suicide, as measured by specific assessment tools used in the trial.
  • Children whose blood test results show that certain liver-related values are above the accepted normal range.
  • Children whose heart tracing (ECG) result is abnormal at the screening appointment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
16 May 2025
Est. completion
12 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Maximum Observed Plasma Concentration (Cmax); Time to Reach Maximum Observed Plasma Concentration (Tmax); Area Under the Curve From Time Zero to infinity.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov